Prevention of Transmission Pillar
Understanding the Epidemiology of Invasive StrepA in Alberta Leading to the Development of Novel Therapeutic and Prevention Strategies.
Project Key Words: Invasive StrepA
Principal Investigator: ; Gregory Tyrrell, PhD, FCCM, D(ABMM)
Co-investigator: Matthew Croxen, PhD, Michael Good, MD, PhD
Project Theme: Innovation and Commercialization
We will develop a clear understanding of the epidemiology of invasive Group A streptococcal disease in Alberta. We will understand the circulating strains, their antibiotic resistance, their toxin profiles, and the populations most severly affected. This information will aid in laying the ground work for a vaccine trail in 2020.
Why is This Important?
This information is important in guiding a planned StrepA vaccine trail and in trailing new experimental therapies for invasive Group A streptococcal disease.
This work will provide the needed information to generate targeted tools such as specific antibodies against these StrepA proteins thereby potentially treating invasive StrepA disease.
Leveraged Sources of Support
- Public Health laboratory (Provlab) - in-kind.
- G. Tyrrell - General Research Funds.
- Li Ka Shing Institute - Edmonton - Funds used to launch vaccine trial provided to M. Good.
Knowledge & Technology: Exchange and Exploitation
- Will provide much needed data regarding the recent increase in the rates of iStrepA in Alberta.
- Will lead to new therapuetic stratgies for the treatment and prevention of iStrepA disease.
Highly Qualified Personnel
- Currently recruiting one PhD student.